Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide adjuvant therapy after reduced-intensity allogeneic transplant for multiple myeloma
ISRCTN16228367Phase 2Completed
- Sponsor
- University Hospitals Birmingham
- Start
- May 2011
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by University Hospitals Birmingham. Primary endpoint: Progression-free survival. Started May 2011; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN16228367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16228367.